AddLife AB Class B ( (ADDLF) ) has released its Q2 earnings. Here is a breakdown of the information AddLife AB Class B presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AddLife AB Class B is a company operating in the healthcare and research sectors, focusing on advanced medical technology and laboratory solutions. In its latest earnings report for the first half of 2025, AddLife AB Class B demonstrated a continued improvement in margins and profit, with a notable 39% increase in profit for the second quarter. The company reported a 3% increase in net sales to SEK 5,280 million, driven by organic growth and strategic acquisitions, including the acquisition of Edge Medical Ltd. in the UK. EBITA rose by 10% to SEK 650 million, reflecting strong cost control and efficiency improvements.
Key financial highlights include a 5% increase in adjusted EBITA for the second quarter and a 63% rise in profit after tax for the first half of the year. The company’s Labtech division showed strong growth, with a 9% increase in net sales, while the Medtech division experienced stable sales with a slight decrease due to external factors such as currency fluctuations and the timing of capital investments. Cash flow from operating activities improved by 23% for the first half of the year, despite a decrease in the second quarter.
Looking ahead, AddLife AB Class B plans to continue its growth strategy through a combination of organic expansion and acquisitions. The company is well-positioned in the European market, with over 90% of sales and 80% of suppliers based in Europe, minimizing exposure to global trade uncertainties. Management remains optimistic about the company’s prospects for the remainder of the year, supported by strong customer relationships and a focus on innovative product offerings.